Nissan Medical Industries Ltd.

As of June 30, 2026, Nissan Medical Industries Ltd. carries a market capitalization of 7.00B, placing it among publicly traded companies globally. Its enterprise value stands at 34.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Nissan Medical Industries Ltd. has 9.08M shares outstanding.

As of June 30, 2026, Nissan Medical Industries Ltd. trades at a trailing price-to-earnings ratio of 9.60. The price-to-sales ratio is 0.11, and the price-to-book ratio stands at 0.38.

As of June 30, 2026, Nissan Medical Industries Ltd. trades at an EV/EBITDA multiple of 6.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Nissan Medical Industries Ltd. trades at an EV/FCF ratio of 8.68, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 34.43B versus a market cap of 7.00B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nissan Medical Industries Ltd. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.57, indicating elevated leverage, while an interest coverage ratio of 5.29 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nissan Medical Industries Ltd. posted a return on equity (ROE) of 3.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.08 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.66, useful for judging operating efficiency across full business cycles. The company generates approximately 157.76M in revenue per employee across its workforce of 385.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.28 indicates how many times Nissan Medical Industries Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Nissan Medical Industries Ltd. recorded 251.20M in income tax expense. That works out to an effective tax rate of 14.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.77B, leaving 726.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Nissan Medical Industries Ltd.'s stock has declined approximately 6.18% over the past 52 weeks. The 50-day moving average sits at 890.21, while the 200-day moving average is 869.06.

Over the twelve months ended June 30, 2026, Nissan Medical Industries Ltd. generated 60.74B in revenue and converted that into 726.80M in net income, yielding earnings per share of 158.46. EBITDA reached 4.98B, while operating income came in at 2.78B.

As of June 30, 2026, Nissan Medical Industries Ltd. holds 1.42B in cash and equivalents against 17.89B in total debt, resulting in a net debt position of 15.09B. Total book value stands at 18.59B, with working capital of -383.10M providing operational flexibility.

Nissan Medical Industries Ltd. produced 6.35B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.20B in capital expenditures, free cash flow totaled 3.16B - equivalent to 348.64 per share.

Over the twelve months ended June 30, 2026, Nissan Medical Industries Ltd. posted a gross margin of 15.15, reflecting its pricing power and cost economics. The operating margin of 4.59 and net profit margin of 1.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 45.26, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 60.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Nissan Medical Industries Ltd. shareholders.

As of June 30, 2026, Nissan Medical Industries Ltd. has an Altman Z-Score of 1.84, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.